Analysts Anticipate Immunic (NASDAQ:IMUX) to Post -$0.80 EPS

Wall Street analysts predict that Immunic (NASDAQ:IMUX) will report ($0.80) earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Immunic’s earnings, with the highest EPS estimate coming in at ($0.73) and the lowest estimate coming in at ($0.86). Immunic reported earnings per share of ($1.52) in the same quarter last year, which would suggest a positive year over year growth rate of 47.4%. The firm is scheduled to announce its next quarterly earnings results on Thursday, August 13th.

On average, analysts expect that Immunic will report full year earnings of ($2.93) per share for the current year, with EPS estimates ranging from ($3.25) to ($2.67). For the next financial year, analysts forecast that the business will report earnings of ($3.62) per share, with EPS estimates ranging from ($4.53) to ($3.01). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Immunic.

Immunic (NASDAQ:IMUX) last announced its earnings results on Friday, May 8th. The company reported ($0.79) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.96) by $0.17.

A number of research analysts have recently commented on IMUX shares. ValuEngine cut shares of Immunic from a “strong-buy” rating to a “buy” rating in a report on Monday, May 11th. Zacks Investment Research cut shares of Immunic from a “buy” rating to a “hold” rating in a report on Wednesday, March 25th. Roth Capital started coverage on shares of Immunic in a report on Wednesday, March 25th. They issued a “buy” rating and a $44.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating on shares of Immunic in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $33.56.

An institutional investor recently raised its position in Immunic stock. Wells Fargo & Company MN boosted its holdings in shares of Immunic (NASDAQ:IMUX) by 78.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,814 shares of the company’s stock after acquiring an additional 4,769 shares during the period. Wells Fargo & Company MN owned about 0.08% of Immunic worth $65,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 16.86% of the stock is currently owned by institutional investors.

Shares of IMUX traded up $0.70 during midday trading on Tuesday, hitting $12.69. The stock had a trading volume of 281,200 shares, compared to its average volume of 121,195. The stock’s 50 day moving average is $9.27 and its 200 day moving average is $8.23. The firm has a market cap of $153.39 million, a PE ratio of -3.44 and a beta of 3.15. Immunic has a 1 year low of $4.19 and a 1 year high of $19.05.

Immunic Company Profile

Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.

Read More: Calculate Your Return on Investment (ROI)

Get a free copy of the Zacks research report on Immunic (IMUX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.